V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210028028 | 210013671 | 1.77 | 54.4 | Curative (C) | 2016-03-29 | 2016-03-29 | Gemcitabine + Oxaliplatin | 02 | N | 210042169 | BEVACIZUMAB + TEMOZOLOMIDE |
| 210028029 | 210013672 | null | 50 | Disease modification (D) | 2018-04-05 | 2018-05-12 | CISPLATIN + VINCRISTINE | N | null | 210042169 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210028030 | 210031544 | null | null | Palliative (P) | 2017-02-13 | 2017-02-13 | Cyclophosphamide High Dose | null | N | 210000982 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210028031 | 210013675 | 1.53 | null | Curative (C) | 2018-04-22 | 2018-09-25 | Gemcitabine + Oxaliplatin | N | N | 210001193 | CYTARABINE |
| 210028032 | 210013677 | 0 | 58 | Curative (C) | null | 2017-09-16 | Mitomycin Intravesical | N | N | 210001293 | PACKER MAINTENANCE |
| 210028033 | 210028143 | null | null | Curative (C) | 2018-11-12 | 2018-11-12 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 210004103 | DOCETAXEL |
| 210028034 | 210022544 | 1.69 | 41.2 | Curative (C) | 2016-02-27 | 2016-05-29 | Bortezomib + MELPHALAN | 02 | N | 210005567 | GEMCITABINE |
| 210028035 | 210022544 | null | 35.5 | Curative (C) | 2018-04-05 | 2018-07-13 | IDARUBICIN | null | N | 210005567 | ECX |
| 210028036 | 210013682 | 1.69 | 99 | Curative (C) | 2013-11-23 | 2013-11-29 | PEMBROLIZUMAB | null | null | 210008338 | CVP |
| 210028037 | 210013683 | 0 | null | Curative (C) | 2018-11-11 | 2018-11-16 | IVE-R | N | 0 | 210008519 | TAMIGA TRIAL |
| 210028038 | 210013685 | null | 72.6 | null | 2016-02-07 | 2016-02-07 | Obinutuzumab | null | N | 210008669 | FLUDARABINE |
| 210028039 | 210013687 | null | 70.8 | Curative (C) | 2017-09-10 | 2018-01-02 | Bevacizumab + LOMUSTINE | Y | null | 210008796 | HYDROXYCARBAMIDE |
| 210028040 | 210013689 | 1.81 | 26.8 | Palliative (P) | 2017-08-30 | 2017-09-15 | RUXOLITINIB | N | N | 210008846 | BENDAMUSTINE + OFATUMUMAB |
| 210028041 | 210013690 | null | 71.5 | Curative (C) | null | 2017-09-01 | Fludarabine oral | 02 | N | 210010376 | IRINOTECAN + MDG |
| 210028042 | 210031547 | null | 32.5 | Curative (C) | 2017-08-05 | 2017-08-05 | Paclitaxel (2 or 3 weekly) | N | N | 210011776 | CYTARABINE INTRATHECAL |
| 210028043 | 210013692 | 1.66 | null | Curative (C) | 2017-10-19 | 2017-10-19 | CLARITY Trial | N | N | 210011848 | CLARITY TRIAL |
| 210028044 | 210013695 | 1.78 | 23 | Curative (C) | 2019-01-18 | 2019-01-18 | CLARITY Trial | N | N | 210012655 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210028045 | 210013697 | 0 | 79 | Curative (C) | 2016-12-05 | 2016-12-20 | ABVD | Y | Y | 210014040 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210028046 | 210013699 | null | 63 | Curative (C) | 2018-09-17 | 2018-12-06 | Cyclophosphamide High Dose | N | Y | 210014521 | CVP |
| 210028047 | 210013701 | 0 | 98.8 | Curative (C) | 2016-04-06 | 2017-09-26 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | 01 | N | 210017128 | CHOEP |
| 210028048 | 210013701 | null | null | Curative (C) | 2017-04-25 | 2018-05-15 | Cytarabine low (10to20mg/m2) IV/SC | 02 | N | 210017128 | CYTARABINE + RITUXIMAB |
| 210028049 | 210013701 | 1.76 | 99.9 | Curative (C) | 2018-03-21 | 2018-04-06 | Consolidation - Cycle 2 & 4 (ALL) | 02 | N | 210017128 | CODOX M |
| 210028050 | 210013704 | 1.62 | 63.2 | Curative (C) | 2017-09-18 | 2017-10-24 | POMALIDOMIDE | Y | N | 210019353 | HYDROXYCARBAMIDE |
| 210028051 | 210013704 | 1.64 | 102 | Disease modification (D) | 2018-08-18 | 2018-08-27 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 2 | N | 210019353 | IDARUBICIN |
| 210028052 | 210013706 | 1.79 | 90 | Curative (C) | 2019-04-24 | 2019-04-25 | Abiraterone | N | N | 210021249 | CLL210 TRIAL |
| 210028053 | 210022562 | 1.52 | 6.25 | Palliative (P) | 2018-10-10 | 2018-11-19 | ALL UKALL2003 C: Ph VII Maintenance | 02 | N | 210021270 | R-EPOCH |
| 210028054 | 210013708 | null | null | Palliative (P) | 2017-12-31 | 2018-01-21 | OFATUMUMAB | 2 | N | 210021324 | CYTARABINE + ETOPOSIDE |
| 210028055 | 210013711 | 1.68 | 61 | Adjuvant (A) | 2018-11-08 | 2018-11-08 | CYCLO + ETOPOSIDE + NELARABINE | null | N | 210021498 | CYTARABINE |
| 210028056 | 210028160 | 1.78 | 83 | Palliative (P) | 2017-04-23 | 2017-07-25 | IDARUBICIN | N | N | 210021743 | CODOX M |
| 210028057 | 210013714 | 0.93 | 21 | Curative (C) | 2005-09-03 | 2016-07-16 | PENTOSTATIN + RITUXIMAB | 2 | N | 210021743 | ALL INDUCTION |
| 210028058 | 210022569 | 1.68 | 82.3 | null | 2019-01-30 | 2019-08-07 | FLUDARABINE + MELPHALAN | Y | null | 210021885 | FLUDARABINE + RITUXIMAB |
| 210028059 | 210013717 | 0 | 75.6 | Curative (C) | 2017-07-30 | 2017-07-31 | ALL UKALL2003 C: Ph VII Maintenance | N | N | 210021911 | RCEOP |
| 210028060 | 210013719 | 1.69 | null | Curative (C) | 2016-05-06 | 2016-05-06 | Cytarabine Intrathecal (any age) | N | N | 210022095 | DHAP - R |
| 210028061 | 210013722 | 1.72 | null | Curative (C) | 2016-11-01 | 2016-11-01 | PNET 4 HIT-SIOP Maintenance | null | N | 210022095 | IGEV R |
| 210028062 | 210013722 | 1.75 | 82.3 | Curative (C) | 2018-12-27 | 2018-12-27 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | N | 210022095 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210028063 | 210013723 | 1.76 | null | Adjuvant (A) | 2019-04-12 | 2019-04-12 | Consolidation - Cycle 1 (ALL) | N | N | 210022560 | CVP |
| 210028064 | 210013724 | 0.94 | 68.6 | Curative (C) | null | 2015-10-11 | LENALIDOMIDE + dexamethasone | 02 | N | 210022634 | CYTARABINE HIGH DOSE |
| 210028065 | 210013726 | 1.76 | 90 | Curative (C) | 2013-08-06 | 2013-08-06 | CLARITY Trial | N | null | 210022799 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 210028066 | 210013729 | 1.87 | 97.9 | Curative (C) | 2017-03-31 | 2017-04-07 | TAMIGA trial | 01 | N | 210023716 | OFATUMUMAB |
| 210028067 | 210031557 | 1.61 | 99 | Curative (C) | 2008-07-20 | 2015-01-29 | Nilotinib | N | null | 210023719 | CLARITY TRIAL |
| 210028068 | 210013732 | 1.83 | 54.1 | Adjuvant (A) | 2015-08-16 | 2017-11-09 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | null | null | 210023909 | DOCETAXEL |
| 210028069 | 210013734 | 1.72 | 28.7 | Curative (C) | 2016-07-25 | 2016-08-01 | PNET 4 HIT-SIOP Maintenance | N | N | 210024019 | FLUDARABINE |
| 210028070 | 210013736 | 1.9 | 68.5 | Disease modification (D) | 2019-04-15 | 2019-05-19 | Carboplatin + Paclitaxel (3 weekly) | N | N | 210024036 | ALL MAINTENANCE |
| 210028071 | 210013737 | 1.57 | 47 | Curative (C) | 2019-02-02 | 2019-09-20 | CLL210 TRIAL | N | N | 210024115 | NILOTINIB |
| 210028072 | 210013738 | 1.56 | 47 | Adjuvant (A) | null | 2016-09-06 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 210024200 | ICE-R |
| 210028073 | 210013740 | 1.83 | 63.5 | null | 2015-10-04 | 2015-10-04 | CISPLATIN + ETOPOSIDE | N | N | 210024335 | IMMUNOGLOBULIN |
| 210028074 | 210022581 | 1.85 | 80 | Curative (C) | null | 2015-11-18 | Dactinomycin + Vincristine | 02 | N | 210024647 | BR14 TRIAL |
| 210028075 | 210013743 | 1.67 | 49.7 | Curative (C) | 2017-04-01 | 2017-04-01 | CNS LGG Irinotecan & Bevacizumab | Y | N | 210024808 | FLUOROURACIL |
| 210028076 | 210013744 | 0 | null | Disease modification (D) | 2019-01-25 | 2019-01-25 | DA-EPOCH-R | N | N | 210024837 | DOCETAXEL |
| 210028077 | 210022584 | null | 63.3 | null | 2018-05-15 | 2018-07-08 | CNS Medbl Std Risk Maint Cisplatin | N | N | 210025000 | CLADRIBINE + RITUXIMAB |